C

Caladrius Biosciences Inc
LSE:0HS8

Watchlist Manager
Caladrius Biosciences Inc
LSE:0HS8
Watchlist
Price: 2.7197 USD -0.56% Market Closed
Market Cap: 52.7m USD
Have any thoughts about
Caladrius Biosciences Inc?
Write Note

Intrinsic Value

0HS8's intrinsic value estimate is unreliable because it is based only on its DCF value and doesn't use a relative valuation using multiples.

The intrinsic value of one 0HS8 stock under the Base Case scenario is 1.8633 USD. Compared to the current market price of 2.7197 USD, Caladrius Biosciences Inc is Overvalued by 31%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

0HS8 Intrinsic Value
1.8633 USD
Overvaluation 31%
Intrinsic Value
Price
C
Worst Case
Base Case
Best Case

Valuation Backtest
Caladrius Biosciences Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for 0HS8 cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about 0HS8?
Bearish
Neutral
Bullish

Fundamental Analysis

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about Caladrius Biosciences Inc

Provide an overview of the primary business activities
of Caladrius Biosciences Inc.

What unique competitive advantages
does Caladrius Biosciences Inc hold over its rivals?

What risks and challenges
does Caladrius Biosciences Inc face in the near future?

Summarize the latest earnings call
of Caladrius Biosciences Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Caladrius Biosciences Inc.

Provide P/S
for Caladrius Biosciences Inc.

Provide P/E
for Caladrius Biosciences Inc.

Provide P/OCF
for Caladrius Biosciences Inc.

Provide P/FCFE
for Caladrius Biosciences Inc.

Provide P/B
for Caladrius Biosciences Inc.

Provide EV/S
for Caladrius Biosciences Inc.

Provide EV/GP
for Caladrius Biosciences Inc.

Provide EV/EBITDA
for Caladrius Biosciences Inc.

Provide EV/EBIT
for Caladrius Biosciences Inc.

Provide EV/OCF
for Caladrius Biosciences Inc.

Provide EV/FCFF
for Caladrius Biosciences Inc.

Provide EV/IC
for Caladrius Biosciences Inc.

Show me price targets
for Caladrius Biosciences Inc made by professional analysts.

What are the Revenue projections
for Caladrius Biosciences Inc?

How accurate were the past Revenue estimates
for Caladrius Biosciences Inc?

What are the Net Income projections
for Caladrius Biosciences Inc?

How accurate were the past Net Income estimates
for Caladrius Biosciences Inc?

What are the EPS projections
for Caladrius Biosciences Inc?

How accurate were the past EPS estimates
for Caladrius Biosciences Inc?

What are the EBIT projections
for Caladrius Biosciences Inc?

How accurate were the past EBIT estimates
for Caladrius Biosciences Inc?

Compare the revenue forecasts
for Caladrius Biosciences Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Caladrius Biosciences Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Caladrius Biosciences Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Caladrius Biosciences Inc compared to its peers.

Compare the P/E ratios
of Caladrius Biosciences Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Caladrius Biosciences Inc with its peers.

Analyze the financial leverage
of Caladrius Biosciences Inc compared to its main competitors.

Show all profitability ratios
for Caladrius Biosciences Inc.

Provide ROE
for Caladrius Biosciences Inc.

Provide ROA
for Caladrius Biosciences Inc.

Provide ROIC
for Caladrius Biosciences Inc.

Provide ROCE
for Caladrius Biosciences Inc.

Provide Gross Margin
for Caladrius Biosciences Inc.

Provide Operating Margin
for Caladrius Biosciences Inc.

Provide Net Margin
for Caladrius Biosciences Inc.

Provide FCF Margin
for Caladrius Biosciences Inc.

Show all solvency ratios
for Caladrius Biosciences Inc.

Provide D/E Ratio
for Caladrius Biosciences Inc.

Provide D/A Ratio
for Caladrius Biosciences Inc.

Provide Interest Coverage Ratio
for Caladrius Biosciences Inc.

Provide Altman Z-Score Ratio
for Caladrius Biosciences Inc.

Provide Quick Ratio
for Caladrius Biosciences Inc.

Provide Current Ratio
for Caladrius Biosciences Inc.

Provide Cash Ratio
for Caladrius Biosciences Inc.

What is the historical Revenue growth
over the last 5 years for Caladrius Biosciences Inc?

What is the historical Net Income growth
over the last 5 years for Caladrius Biosciences Inc?

What is the current Free Cash Flow
of Caladrius Biosciences Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Caladrius Biosciences Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Caladrius Biosciences Inc

Current Assets 37.7m
Cash & Short-Term Investments 35.9m
Other Current Assets 1.8m
Non-Current Assets 507k
PP&E 278k
Intangibles 210k
Other Non-Current Assets 19k
Current Liabilities 4.7m
Accounts Payable 556k
Accrued Liabilities 4.1m
Non-Current Liabilities -182k
Other Non-Current Liabilities -182k
Efficiency

Earnings Waterfall
Caladrius Biosciences Inc

Revenue
0 USD
Operating Expenses
-23.5m USD
Operating Income
-23.5m USD
Other Expenses
2.7m USD
Net Income
-20.7m USD

Free Cash Flow Analysis
Caladrius Biosciences Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

0HS8 Profitability Score
Profitability Due Diligence

Caladrius Biosciences Inc's profitability score is 29/100. The higher the profitability score, the more profitable the company is.

29/100
Profitability
Score

Caladrius Biosciences Inc's profitability score is 29/100. The higher the profitability score, the more profitable the company is.

0HS8 Solvency Score
Solvency Due Diligence

Caladrius Biosciences Inc's solvency score is 61/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Long-Term Solvency
Low D/E
Low Altman Z-Score
61/100
Solvency
Score

Caladrius Biosciences Inc's solvency score is 61/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

0HS8 Price Targets Summary
Caladrius Biosciences Inc

Wall Street analysts forecast 0HS8 stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for 0HS8 is 14.1226 USD with a low forecast of 12.9854 USD and a high forecast of 15.5764 USD.

Lowest
Price Target
12.9854 USD
377% Upside
Average
Price Target
14.1226 USD
419% Upside
Highest
Price Target
15.5764 USD
473% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for 0HS8?

Click here to dive deeper.

Dividends

Caladrius Biosciences Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for 0HS8 is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Profile

Caladrius Biosciences Inc

Country

United States of America

Industry

Biotechnology

Market Cap

52.7m USD

Dividend Yield

0%

Description

Caladrius Biosciences, Inc. is a biopharmaceutical company, which engages in development of cell therapies for select cardiovascular and autoimmune diseases. The company is headquartered in Basking Ridge, New Jersey and currently employs 27 full-time employees. The firm is developing therapeutics based on the characteristics of naturally occurring CD34+ cells and their ability to stimulate the growth of new microvasculature. The Company’s product candidates include CLBS16, CLBS12 and CLBS201. The CLBS16 (XOWNA) is an experimental regenerative medicine that is being studied in a Phase IIb study (the FREEDOM trial) in the United States for the treatment of coronary microvascular dysfunction. The CLBS12 (HONEDRA) is an experimental regenerative medicine being studied in Japan for the prevention of serious adverse consequences of critical limb ischemia. The CLBS201 is an experimental regenerative medicine designed to assess the safety and efficacy of CD34+ cell therapy as a treatment for diabetic kidney disease.

Contact

NEW JERSEY
Basking Ridge
110 Allen Road, Second Floor
+19082292590.0
www.caladrius.com

IPO

1995-11-03

Employees

27

Officers

President, CEO & Director
Dr. David J. Mazzo B.A. (Hons), B.Sc. (Hons.), M.Sc., Ph.D.
Executive VP of R&D and Chief Medical Officer
Dr. Kristen K. Buck M.D.
Senior VP of Finance, Treasurer, CAO & Principal Financial and Accounting Officer
Mr. James Nisco
Vice President of Business Development & Operations and Corporate Counsel
Mr. Tariq Imam
Chief Information & Data Protection Officer
Mr. Gregory S. Berkin
Vice President of Investor Relations & Corporate Communications
Mr. John D. Menditto
Show More
Vice President of Human Resources
Ms. Gail Holler
Vice President of Global Regulatory Affairs
Dr. William K. Sietsema Ph.D.
Show Less

See Also

Discover More
What is the Intrinsic Value of one 0HS8 stock?

The intrinsic value of one 0HS8 stock under the Base Case scenario is 1.8633 USD.

Is 0HS8 stock undervalued or overvalued?

Compared to the current market price of 2.7197 USD, Caladrius Biosciences Inc is Overvalued by 31%.

Back to Top